vadimezan has been researched along with sb 203580 in 2 studies
Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) |
---|---|---|---|---|---|
272 | 16 | 101 | 3,489 | 4 | 1,137 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baguley, BC; Kelland, LR; Marshall, ES; Zhao, L | 1 |
Albelda, SM; Cheng, G; Ching, LM; Fridlender, ZG; Sun, J; Wang, LC | 1 |
2 other study(ies) available for vadimezan and sb 203580
Article | Year |
---|---|
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Cell Line, Tumor; Cell Proliferation; Cell Shape; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Laminin; MAP Kinase Signaling System; Melanoma; Mice; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proteoglycans; Pyridines; RNA, Messenger; Xanthones; Xenograft Model Antitumor Assays | 2007 |
Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).
Topics: Antineoplastic Agents; Cells, Cultured; Chemokine CXCL10; Enzyme Inhibitors; Humans; Imidazoles; Immunoblotting; Kidney; Luciferases; Mesothelioma; NF-kappa B; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Nucleotides; Pyridines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Xanthones | 2010 |